Redefining drug delivery paradigims: Proniosomes as revolutionary tools for enhanced efficacy

Proniosomes represent an innovative drug delivery system that enhances therapeutic effectiveness through controlled release, improved stability, and decreased toxicity. These carriers, based on non-ionic surfactants, are able to contain both hydrophilic and lipophilic drugs, thereby overcoming the limitations associated with traditional carriers that are lipid-based, including niosomes and liposomes. Upon hydration, proniosomes transform into niosomes, facilitating targeted and sustained drug delivery while minimizing adverse effects. They enhance drug stability, bioavailability, and patient compliance, particularly in oral and transdermal delivery methods. Proniosomes effectively tackle challenges like fusion, aggregation and leakage, ensuring physical stability on storage. Their applications span various therapeutic fields, including antibacterial treatments, anti-neoplastic therapies, gene delivery, and ocular drug administration. However, challenges persist, including the complete toxicity profile of non-ionic surfactants, fusion issues, and complexities in preparation. In summary, proniosomes serve as a versatile and effective platform for controlled drug delivery, providing significant advantages across a broad spectrum of medical and pharmaceutical applications.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-08-31
DOI
https://doi.org/10.5281/zenodo.17499842
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Redefining drug delivery paradigims: Proniosomes as revolutionary tools for enhanced efficacy

Zenodo (CERN European Organization for Nuclear Research)
Advancements in Transdermal Drug Delivery
article

Redefining drug delivery paradigims: Proniosomes as revolutionary tools for enhanced efficacy

article en

Abstract

Proniosomes represent an innovative drug delivery system that enhances therapeutic effectiveness through controlled release, improved stability, and decreased toxicity. These carriers, based on non-ionic surfactants, are able to contain both hydrophilic and lipophilic drugs, thereby overcoming the limitations associated with traditional carriers that are lipid-based, including niosomes and liposomes. Upon hydration, proniosomes transform into niosomes, facilitating targeted and sustained drug delivery while minimizing adverse effects. They enhance drug stability, bioavailability, and patient compliance, particularly in oral and transdermal delivery methods. Proniosomes effectively tackle challenges like fusion, aggregation and leakage, ensuring physical stability on storage. Their applications span various therapeutic fields, including antibacterial treatments, anti-neoplastic therapies, gene delivery, and ocular drug administration. However, challenges persist, including the complete toxicity profile of non-ionic surfactants, fusion issues, and complexities in preparation. In summary, proniosomes serve as a versatile and effective platform for controlled drug delivery, providing significant advantages across a broad spectrum of medical and pharmaceutical applications.

Zenodo (CERN European Organization for Nuclear Research)
Hindu College of Pharmacy (IN)
Good health and well-being
Openalex Percentile: Top 50%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Redefining drug delivery paradigims: Proniosomes as revolutionary tools for enhanced efficacy · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS